Press Release – November 2004

The following is supportive data to the enclosed abstract and patient performance data on this breaking story.

The Prostatitis & Prostate Cancer Center Sarasota, Florida

With a new case of prostate cancer diagnosed every 3 minutes, there is concern that without novel, beneficial, less costly methodologies to treat the cancer the health care system will be at risk. The late William Fair, M.D. (former Chairman of Surgery and Urology at Memorial Sloan-Kettering), who championed the cause of Integrative Medicine, stated in the year 2000, Based on eerything we know about prostate cancer, I am not certain that it should not be treated as a chronic disease. Dr. Fair’s frustration was noted in the inability to predictably cure prostate cancer when it was detected. Challenging the concept of treatment for cure, the late Willet Whitmore, M.D. (Memorial Sloan-Kettering) asked the rhetorical question in a now famous quote, Is it possible to cure prostate cancer when it is necessary and is it necessary to cure prostate cancer when it is possible?

Concentrating on the later part of the rhetorical question, I have evaluated men with known prostate cancer with a modified Mediterranean diet and a patented prostate nutritional formula called Peenuts?. I believe I have developed a viable treatment modality for men with moderately well differentiated prostate cancer. The results of this prospective study are exceptional as the prostate cancer process has just reversed itself or stopped growing. Importantly, all men entered in the study did well. The only qualification for study entry was that a man needed a biopsy proven moderately well differentiated prostate cancer consistent with a Gleason score of 5 or 6 (range: 2-10).

The financial impact of transitioning men who choose to live with their cancer will be in the billions of dollars saved, as minimally 50-60% of all prostate cancers fit this category. Additionally, men will be spared a quality of life altering procedure including Radical Prostatectomy or Radiation. While patients in this studyprotocol still qualify for these definitive procedures in the event they cnge their minds, there is no indication that a more aggressive treatment isrequired. As the study results point out, 90% of the patients suppressed their cancer while 10% remained stable at an average disease surveillance of 30 months. Minimally the findings associated with this study give patients an additional option, with renewed hope for a better quality of life, when prostate cancer is diagnosed.

Please feel free to contact me with questions or comments at 1-941-957-0007.


Ronald E. Wheeler, M.D.